P-49: Study of Cetrorelix in Inhibition of Side Effect of Vinblastin Used in Chemotherapy on Germinal Epithelium in Mouse Testis

Background: Infertility problem affects young couples. One of the known causes of spermatogenic disorder is chemotherapy in patients with cancer. Since dividing cells are mainly affected by anticancer drugs, the aim of the present study is to investigate the preventive effect of GnRH on spermatogenic defect produced by anticancer drug. Materials and Methods: In the present study 30 adult female mice aging 6-8 weeks were used. The mice were divided into 3 equal groups as control, exp group 1 and exp group 2. In exp group 1vinblastin was injected as ip for 5 days at 0. 25 mg/kg. In exp group 2 group cetrorelix injection was started one week before vinblastin treatment and continued for 3 more weeks. The mice in all groups were sacrificed 3 weeks after the last dose of Cetrorelix injection. Testicular specimens were prepared for LM studies. Results: Microscopic study revealed that in the control group the mean number of sertoli and spermatogonium, were 8.20 ± 1.30 and 56 ± 7.35 respectively. In exp group 1 the mean number of above mentioned cells were 18.60 ± 3.65 and 39.80 ± 3.70. In exp group 2 the mean number of above mentioned cells were 9.20 ± 1.3 and 54.80 ± 4.95. The data showed the difference between control and exp 1group was significant, but the difference between control and exp 2 was not. Spermatogenesis index (SI) and diameter of germinal epithelium in control group were 0.70 ± 0.30 and 168.80 ± 14.13 respectively. In exp group 1 were 0.17 ± 0.16 and 117.80 ± 14.18 but in exp group 2 were 0.62 ± 0.25 and 161.20 ± 12.21. The data showed the difference between control and exp 1group was significant, but the difference between control and exp 2 was not. Conclusion: It is concluded that GnRH antagonist administration before cancer treatment could prevent the side effect of anticancer drugs.